AUGTYROS
Live / Applied — Third extension granted (statement of use) (as of 12 Jan 2026)
What this means for you
Not registered yet, but its 18 Jan 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97759444
- Mark type
- Stylized text
- Filed
- 18 Jan 2023
- Published for opposition
- 28 May 2024
- Attorney of record
- Marilyn F. Kelly
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use
Owner
- Turning Point Therapeutics, Inc., San Diego, CA, US
- Turning Point Therapeutics, Inc., San Diego, CA, US
Prosecution history
- 12 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Jan 2026 — SOU EXTENSION 3 GRANTED
- 12 Jan 2026 — SOU EXTENSION 3 FILED
- 12 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 24 Jun 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Jun 2025 — SOU EXTENSION 2 GRANTED
- 24 Jun 2025 — SOU EXTENSION 2 FILED
- 24 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Jan 2025 — SOU EXTENSION 1 GRANTED
- 07 Jan 2025 — SOU EXTENSION 1 FILED
- 07 Jan 2025 — SOU TEAS EXTENSION RECEIVED
- 23 Jul 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 28 May 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 28 May 2024 — PUBLISHED FOR OPPOSITION